Scheduled prophylactic ondansetron administration did not improve its antiemetic efficacy after intracranial tumour resection surgery in children

Eur J Anaesthesiol. 2007 Jul;24(7):615-9. doi: 10.1017/S0265021506002092. Epub 2007 Jan 30.

Abstract

Background and objective: Postoperative nausea and vomiting after craniotomy may increase intracranial pressure and morbidity in children. This prospective, randomized, placebo-controlled and double-blinded study was designed to evaluate the antiemetic efficacy of prophylactic ondansetron after intracranial tumour resections in children.

Methods: Ninety children were divided into three groups and received saline (Group 1), ondansetron 150 microg kg-1 intravenously at dural closure (Group 2) or two doses of ondansetron 150 microg kg-1 intravenously, the second dose repeated after 6 h (Group 3). Episodes of nausea, emesis and side-effects were noted for 24 h postoperatively.

Results: Overall 24 h incidence of postoperative nausea and vomiting was not significantly different among the three groups (9 (37.5%) in Group 1 vs. 7 (27%) in Group 2 and 8 (32%) in Group 3, P = 0.73). No difference in rescue antiemetic treatment or postoperative nausea and vomiting at specific time intervals (0-6 and 6-24 h postoperative period) was seen among the three groups. No significant side-effects were noted in any of the three groups.

Conclusions: Ondansetron, in this study of 90 children, was not very effective in preventing nausea and vomiting after neurosurgical operations.

Publication types

  • Randomized Controlled Trial

MeSH terms

  • Adolescent
  • Adult
  • Antiemetics / administration & dosage*
  • Brain Neoplasms / surgery*
  • Child
  • Child, Preschool
  • Craniotomy*
  • Double-Blind Method
  • Drug Administration Schedule
  • Female
  • Humans
  • Incidence
  • Injections, Intravenous
  • Male
  • Ondansetron / administration & dosage*
  • Postoperative Nausea and Vomiting / epidemiology
  • Postoperative Nausea and Vomiting / prevention & control*
  • Preanesthetic Medication*
  • Prospective Studies
  • Time Factors
  • Treatment Outcome

Substances

  • Antiemetics
  • Ondansetron